Dysmenorrhea Treatment Companies | Market Research Future

Top Industry Leaders in the Dysmenorrhea Treatment Market

*Disclaimer: List of key companies in no particular orderLatest Dysmenorrhea treatment Companies Update

Oct 2023: Johnson & Johnson, a pharmaceutical company in the United States, has declared that it will not defend the patents for Sirturo, the brand name for bedaquiline, used to treat multidrug-resistant tuberculosis, in 134 low- and middle-income nations. This action comes in response to international pressure on the business to forgo secondary patent applications for its ground-breaking tuberculosis medication, notably the Indian Patent Office's denial of J&J's application for the fumarate salt of bedaquiline. Bedaquiline, less toxic and more successful than conventional TB treatments, is the first tuberculosis (TB) medicine to be licensed globally in more than 40 years. The announcement will finally open the door for everyone who needs bedaquiline to have unrestricted possession of affordable generic versions of the medication.

Oct 2023: At the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Therapy and Research in Multiple Sclerosis), Roche presented new clinical and real-world data for OCREVUS® (ocrelizumab), illustrating its role in moving forward to transform care for people living with relapsing or main progressive multiple sclerosis (RMS or PPMS). OCREVUS has accumulated ten years of follow-up data from its three Phase III trials, making it the first disease-modifying therapy (DMT) in MS to benefit both RMS and PPMS patients. The medication's favorable benefit-risk profile, which has remained constant over the past 10 years, is further supported by new safety data from 6,155 patients who had 28,269 patient years of contact with OCREVUS across 12 clinical trials.

List of Dysmenorrhea treatment Key companies in the market